Topics
News
CME/CE
Editorial Advisory Board
Partnerships
LEISHMANIASIS DRUG
AEterna Laboratories reported recently the results of a phase III trial evaluating its drug Impavido (miltefosine) for the treatment of cutaneous leishmaniasis, showing that patients taking Impavido had a 220-percent better cure rate compared with those in a placebo group.
Related Videos
Related Content
